摘要
多发性硬化症是最常见的自身免疫性疾病,影响中枢神经系统(CNS)。其病理生理机制是以神经元髓鞘的破坏方式,在很大程度上依赖于CD4+ / CD8+ T细胞对自身反应性髓鞘抗原,诱导Th1/Th17病原反应产生的自由基和可溶性介质表现出神经退行性疾病的效应机制。负责本病的免疫反应是复杂的,是现代医学的挑战。因此,许多实验性疗法已被提出,除了传统用于治疗多发性硬化症的免疫/免疫抑制药物的提出。在这篇综述中,我们将描述广泛使用疾病修饰多发性硬化症药物以及一些目前在实验阶段的选择治疗的效应和作用机制。重点是放置在寄生虫衍生的免疫调节剂,如他们中的一些已经显示出可喜的成果。此外,我们将比较两MS药物和寄生虫衍生的治疗作用机制探讨一些信号通路在MS的控制的潜在重要性
关键词: 多发性硬化症,实验性自身免疫性脑脊髓炎,寄生虫的抗原,多糖,免疫调节。
Current Medicinal Chemistry
Title:Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived Treatments
Volume: 23 Issue: 11
Author(s): Alberto N. Peón, Luis I. Terrazas
Affiliation:
关键词: 多发性硬化症,实验性自身免疫性脑脊髓炎,寄生虫的抗原,多糖,免疫调节。
摘要: Multiple sclerosis (MS) is the most prevalent autoimmune disease affecting the central nervous system (CNS). Its pathophysiology is centered on neuron myelin sheath destruction in a manner largely dependent upon CD4+/CD8+ T-cell autoreactivity against myelin antigens, inducing Th1/Th17 pathogenic responses with the resulting production of free radicals and soluble mediators that exhibit the effector mechanisms of neurodegeneration. The immune response responsible for this disease is complex and challenges modern medicine. Consequently, many experimental therapies have been proposed in addition to the classical array of immunoregulatory/ immunosuppressive drugs that are normally used to treat MS. In this review, we will describe the effects and mechanisms of action of widely used disease-modifying MS drugs as well as those of select treatments that are currently in the experimental phase. Special emphasis is placed on helminth-derived immunoregulators, as some of them have shown promising results. Additionally, we will compare the mechanisms of action of both the MS drugs and the helminth-derived treatments to discuss the potential importance of some signaling pathways in the control of MS.
Export Options
About this article
Cite this article as:
Alberto N. Peón, Luis I. Terrazas , Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived Treatments, Current Medicinal Chemistry 2016; 23 (11) . https://dx.doi.org/10.2174/0929867323666160311114110
DOI https://dx.doi.org/10.2174/0929867323666160311114110 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders
Current Molecular Pharmacology The Role of Neutrophil Proteases in LPS-Induced Production of Regulatory Rheumatoid Factor that Suppresses Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting BLyS in Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety Editorial [Hot Topic: Genome and Proteome Analyses of Autoimmune Diseases (Executive Editor: G. Neeck)]
Current Pharmaceutical Design Editorial: (Thematic Issue: Autoimmune diseases: What have we learned from mice?)
Current Pharmaceutical Design The Role of Autophagy in Rheumatic Disease
Current Drug Targets Identification of Moesin as a Novel Autoantigen in Patients with Sjögren’s Syndrome
Protein & Peptide Letters Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?
Current Medicinal Chemistry Bioinformatic Screening of Autoimmune Disease Genes and Protein Structure Prediction with FAMS for Drug Discovery
Protein & Peptide Letters Modulation of TNF Receptor Family Members to Inhibit Autoimmune Disease
Current Drug Targets - Inflammation & Allergy Type I Interferon as a Target of Treatment in SLE
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets Interactions of Sex Steroids with Mechanisms of Inflammation
Current Drug Targets - Inflammation & Allergy